| scholarly article | Q13442814 |
| P50 | author | Markus Alexander Zeitlinger | Q75261425 |
| Hartmut J Ehrlich | Q104745018 | ||
| P Noel Barrett | Q104745030 | ||
| P2093 | author name string | Wolfgang Herr | |
| Robert Sauermann | |||
| Brian A Crowe | |||
| Daniel Portsmouth | |||
| Richard Fritz | |||
| Christoph Stephan | |||
| Gerald Aichinger | |||
| Maikel V W van der Velden | |||
| Thomas Dvorak | |||
| Eva M Wagner | |||
| Eva Distler | |||
| Alexander Geisberger | |||
| P2860 | cites work | Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective | Q28740919 |
| H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model | Q28741304 | ||
| Strategies for mitigating an influenza pandemic | Q29615422 | ||
| Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. | Q30224497 | ||
| Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults | Q30227196 | ||
| Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. | Q30353681 | ||
| Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. | Q30362794 | ||
| Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. | Q30363500 | ||
| A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. | Q30369945 | ||
| An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. | Q30370214 | ||
| MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults | Q30374764 | ||
| Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. | Q30375515 | ||
| A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. | Q30380169 | ||
| Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. | Q30387842 | ||
| Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. | Q30395944 | ||
| Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study | Q30403078 | ||
| Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. | Q30404994 | ||
| Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly | Q30410983 | ||
| T-helper 1 cells elicited by H5N1 vaccination predict seroprotection | Q30416272 | ||
| Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. | Q33935910 | ||
| Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. | Q33974507 | ||
| Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine | Q34073541 | ||
| Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels | Q37106916 | ||
| Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients | Q37373457 | ||
| Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses | Q37416103 | ||
| Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjects | Q41972849 | ||
| Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. | Q42268487 | ||
| Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. | Q42916307 | ||
| Viral loads and duration of viral shedding in adult patients hospitalized with influenza. | Q43873120 | ||
| Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation | Q45388337 | ||
| Order-restricted tests for stratified comparisons of binomial proportions | Q71528111 | ||
| P433 | issue | 6 | |
| P921 | main subject | influenza vaccine | Q383260 |
| P304 | page(s) | 867-876 | |
| P577 | publication date | 2014-04-16 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients | |
| P478 | volume | 21 |
| Q91776121 | A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1) |
| Q30387186 | Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment |
| Q50180213 | Emerging Respiratory Viruses in Children |
| Q35570521 | Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients |
| Q30381595 | Refining the approach to vaccines against influenza A viruses with pandemic potential. |
| Q26796420 | Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities |
| Q38157590 | Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases |
Search more.